Summary
Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease that affects 1 million patients in Europe. ST-0529 is enabled using Sublimity Therapeutics ’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, Cyclosporine, directly to inflamed colons. In Phase II human studies, ST-0529 was proven to be effective and safe. ST-0529, an oral product, will compete with injected, expensive drugs that have a risk of serious side effects.
Successful development and commercialisation of ST-0529 will pivot on development of a stable ST-0529 product and a positive outcome of the clinical trials.
Overall, the project will involve leading EU-based specialist SME, technology and equipment suppliers as well as a number of knowledge providers. The budget is €1.6M and will be completed in 58 months.
Successful completion of this project will retain and enhance intellectual property and know-how in Sublimity Therapeutics, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of ST-0529, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M.
Successful development and commercialisation of ST-0529 will pivot on development of a stable ST-0529 product and a positive outcome of the clinical trials.
Overall, the project will involve leading EU-based specialist SME, technology and equipment suppliers as well as a number of knowledge providers. The budget is €1.6M and will be completed in 58 months.
Successful completion of this project will retain and enhance intellectual property and know-how in Sublimity Therapeutics, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of ST-0529, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/666795 |
| Start date: | 01-07-2015 |
| End date: | 30-04-2020 |
| Total budget - Public funding: | 2 307 500,00 Euro - 1 600 000,00 Euro |
Cordis data
Original description
Sublimity Therapeutics has developed an innovative product, ST-0529, to treat patients with moderate-severe Ulcerative Colitis, a disease that affects 1 million patients in Europe. ST-0529 is enabled using Sublimity Therapeutics ’s proprietary SmPill® nanoemulsion-based technology to target a known and powerful drug, Cyclosporine, directly to inflamed colons. In Phase II human studies, ST-0529 was proven to be effective and safe. ST-0529, an oral product, will compete with injected, expensive drugs that have a risk of serious side effects.Successful development and commercialisation of ST-0529 will pivot on development of a stable ST-0529 product and a positive outcome of the clinical trials.
Overall, the project will involve leading EU-based specialist SME, technology and equipment suppliers as well as a number of knowledge providers. The budget is €1.6M and will be completed in 58 months.
Successful completion of this project will retain and enhance intellectual property and know-how in Sublimity Therapeutics, increase long term high skill jobs. In parallel, the project will unlock the value inherent not only of ST-0529, but also the underlying SmPill® technology platform. Furthermore, the project will increase the probability of overall company success and increase significantly the NPV to more than €500M.
Status
CLOSEDCall topic
NMP-25-2014Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.2. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
